The Center for Inherited Disease Research (CIDR) performed next-generation targeted sequencing on CHRNA5. Details of the sequencing procedures and quality control measures are provided in the Supplementary Methods. The mean on-target coverage was 180X, and greater than 96% of on-target bases had a depth greater than 20X.